Disclosure Statement:
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. Faculty disclosure related to this CME activity is listed below. The intent of this disclosure is to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.
Dr. O’Hollaren has served as a consultant for GlaxoSmithKline. He has served on the speakers bureaus for AstraZeneca, IVAX Laboratories, Genentech, GlaxoSmithKline, and Novartis.
Release/Expiration Dates
This activity is eligible for CME credit from October 2007 through October 31, 2008.
Additional Topics
> New Strategies in Asthma Control: Issues in Management of Special Risk Populations
> Success in Asthma Control with Challenging Patients
> New Strategies in Asthma Control: Assessment of Impairment and Risk
|
